

Contents

Preface XI

A Personal Foreword XIII

List of Contributors XV

1	Molecular Recognition of Nuclear Hormone Receptor-Ligand Complexes	1
	<i>Robert E. Babine</i>	
1.1	Introduction	1
1.1.1	Nuclear Hormone Receptors: Ligand Binding Domains	1
1.1.2	Dimerization and Interactions with Co-activators and Co-repressors	2
1.2	Steroid Receptors	5
1.2.1	The Role of the Ligand	5
1.2.1.1	Estradiol Estrogen Receptor Complex	5
1.2.1.2	Other Estrogen Receptor Agonists Complexes	8
1.2.1.3	Estrogen Receptor Antagonists Complexes	9
1.2.1.4	Genistein – An ER- β Partial Agonist	12
1.2.1.5	R,R-5,11- <i>cis</i> -Diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol: An ER- α Agonist and ER- β Antagonist	14
1.2.2	Structural Basis for Agonism and Antagonism and Partial Agonism: The Role of the Ligand	15
1.2.3	Progesterone/Progesterone Receptor Complex	16
1.2.4	Androgen Receptor Complexes	17
1.2.5	Glucocorticoid Receptor	18
1.2.6	Steroid Ligand Selectivity	19
1.3	The Vitamin D Receptor-Ligand Complexes	22
1.4	The Retinoic Acid Receptors RAR and RXR	23
1.4.1	Introduction	23
1.4.2	RAR- γ and RXR- α Retinoid Complexes	25
1.4.3	Selectivity of RAR Ligands and RAR Isoforms	27
1.4.4	RXR Complexes with Unnatural Ligands	33
1.5	PPAR: Isoform-Selective Ligands	34
1.6	Summary	41
1.7	Acknowledgements	43

1.8	References	43
2	Kinases	47
	<i>Jerry L. Adams, James Veal, and Lisa Shewchuk</i>	
2.1	Introduction	47
2.2	Structure and Function	48
2.2.1	Tertiary Structure	48
2.2.2	Catalysis and Substrate Binding	49
2.2.3	Regulation and Conformational Flexibility	50
2.2.3.1	Activation Loop Conformation	50
2.2.3.2	Glycine Rich Loop	51
2.2.3.3	C-Helix Orientation	51
2.2.3.4	Lobe Orientation	53
2.2.3.5	Solvent Channel	53
2.3	Crystallization	54
2.3.1	Defining the Construct	54
2.3.2	Mutagenesis	55
2.3.3	Phosphorylation	55
2.4	Inhibitor Design	56
2.4.1	Binding in ATP Cleft	56
2.4.1.1	ATP Binding Sites	57
2.4.1.2	Gatekeeper-Dependent Binding Pocket	60
2.4.1.3	Lipophilic Plug	61
2.4.1.4	Polar Surface Site	61
2.4.2	Conformational Considerations	63
2.4.2.1	Inhibitor-Induced Binding	63
2.4.2.2	What is the Most Appropriate Enzyme Form for Crystallography?	64
2.4.2.3	Homology Models and Surrogate Kinases	66
2.4.3	Paradigms for Kinase Drug Discovery	68
2.4.3.1	High Throughput Screening	68
2.4.3.2	Structure-Based Design	69
2.4.3.3	Mechanism-Based and Ligand Mimetic Design	72
2.4.3.4	Computational Chemistry and Virtual Screening	72
2.4.4	Selectivity	73
2.5	Conclusion	75
2.6	References	76
3	The Proteasome as a Drug Target	83
	<i>Tsunehiro Mizushima and Tomitake Tsukihara</i>	
3.1	Introduction	83
3.2	The Ubiquitin-Proteasome System	83
3.2.1	Role of the Ubiquitin-Proteasome System	84
3.2.2	26S Proteasome	85
3.2.3	20S Proteasome	85
3.3	Structure of the 20S Proteasome	86

3.3.1	Active Sites of Eukaryotic 20S Proteasomes	88
3.3.2	Novel Ntn-Hydrolase Active Site of the $\beta 7$ Subunit	88
3.3.3	Predicted Structure of Immunoproteasome and Substrate Specificities	89
3.4	Proteasome Inhibitors	93
3.4.1	Structure of Proteasome Inhibitor Complexes	95
3.5	Conclusions	96
3.6	Acknowledgements	96
3.7	References	96
4	Antibiotics and the Ribosome	99
	<i>Jeffrey L. Hansen</i>	
4.1	Introduction	99
4.2	The Ribosome	99
4.2.1	Introduction	99
4.2.2	Binding of tRNA	100
4.2.3	Peptidyl Transferase Activity	101
4.2.4	Structure of the Ribosome	102
4.3	Antibiotics	103
4.3.1	Introduction	103
4.3.2	Antibiotics that Bind to the 50S Subunit	104
4.3.3	MLS _B Antibiotics	105
4.3.4	Macrolides	107
4.3.4.1	Macrolides, 15- and 16-Membered	107
4.3.4.2	Binding Interactions Between the Lactone Ring and the Ribosome	108
4.3.4.3	Sugar Interactions with the Ribosome	110
4.3.4.4	A Covalent Bond	111
4.3.4.5	Macrolides, 14-Membered	112
4.3.4.6	Rational Drug Design of Macrolides	112
4.3.5	Lincosamides	114
4.3.6	Streptogramins	114
4.3.7	Chloramphenicol	115
4.3.8	Nucleoside Analogue Antibiotics	117
4.3.8.1	Puromycin	117
4.3.8.2	Aminoacyl-4-aminoheptosyl-cytosine Antibiotics	118
4.3.9	Other Antibiotics that Bind to the 50S Subunit	119
4.3.9.1	Sparsomycin	119
4.3.9.2	Anisomycin	120
4.4	Prospects for Rational Drug Design of Antibiotics that Bind to the Ribosome	120
4.5	Acknowledgements	122
4.6	References	122

5	Structure-Based Design of Cathepsin K Inhibitors	127
	<i>Daniel F. Veber and Maxwell D. Cummings</i>	
5.1	Introduction	127
5.2	Background and Issues to be Addressed Using Protein Structure	128
5.3	Cysteine Protease Inhibitors: Historical Perspective	131
5.4	Diaminoketone-Based Inhibitors	133
5.5	Cyclic Diaminoketone Inhibitors	136
5.6	Alkoxymethyl and Thiomethyl Dipeptidyl Ketone-Based Inhibitors	140
5.7	Diacylcarbohydrazides	142
5.8	Conclusions	143
5.9	References	145
6	Structure-Based Design of Potent and Selective Cdk4 Inhibitors	147
	<i>Teruki Honma</i>	
6.1	Introduction	147
6.2	Homology Modeling of Cdk4	148
6.3	Analysis of the ATP Binding Pocket	151
6.4	Strategies for Structure-Based Lead Identification: Virtual Screening of Known Compounds and de Novo Design	152
6.4.1	New de Novo Design Strategies	153
6.4.2	Evaluation of Chemical Availability by SEEDS	155
6.5	Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors	157
6.5.1	Identification of New Scaffold Candidates Using LEGEND and SEEDS	157
6.5.2	From the Identified Scaffold to Lead Compounds	159
6.5.3	Confirmation of the Binding Mode	159
6.6	Structure-Based Design of Cdk4 Selective Inhibitors	160
6.6.1	Identification of Cdk4-Specific Amino Acid Residues	161
6.6.2	Library Design Based on the Locations of Cdk4-Specific Amino Acid Residues	163
6.7	Conclusion	167
6.8	Acknowledgements	167
6.9	References	168
7	Crystallization and Analysis of Serine Proteases with Ecotin	171
	<i>Sandra M. Waugh and Robert J. Fletterick</i>	
7.1	What is Ecotin?	171
7.2	Methods	173
7.2.1	Expression of Wild Type Ecotin	173
7.2.2	Purification of Wild Type Ecotin	174
7.2.3	Crystallization of Ecotin and Protease Complexes	175
7.3	Representative Examples of Ecotin and Protease Structures	175
7.3.1	Ecotin Defines the S7 Through S4' Subsites of Collagenase	176

7.3.2	Ecotin as a Tight Binding Substrate	177
7.3.3	Ecotin Defines Regions Distal to the Factor Xa Protease Domain	178
7.4	Crystallization and Structure Determination of E ₂ P ₂ Complexes	180
7.5	Conclusion	183
7.6	References	184
8	X-ray Crystallography in the Development of Orthogonal Ligand-Receptor Pairs	187
	<i>Donald F. Doyle and Lauren J. Schwimmer</i>	
8.1	Introduction	187
8.2	Applications of OLRPs	188
8.2.1	Applications in Basic Research	188
8.2.2	Applications in Applied Research	189
8.3	Early Work	189
8.4	Structure-Guided Mutagenesis and OLRPs	190
8.4.1	Binding Pocket Mutations	191
8.4.1.1	Nuclear Receptors	191
8.4.1.2	Estrogen Receptor OLRPs	193
8.4.1.3	Retinoic Acid Receptor OLRPs	195
8.4.1.4	Retinoid X Receptor OLRPs	195
8.4.2	Distant Mutations	197
8.5	Other Examples of OLRPs	200
8.5.1	Chemical Inducers of Dimerization to Control Transcription	200
8.5.2	OLRPs and ATP Analogues	202
8.6	Summary	204
8.7	References	206
9	Engineering Proteins to Promote Crystallization	209
	<i>Lei Jin and Robert E. Babine</i>	
9.1	Introduction	209
9.2	Removing Protein Heterogeneity by Truncation	210
9.3	Removing Protein Heterogeneity by Point Mutation	211
9.4	Improving Crystal Packing by Point Mutation	212
9.5	Acknowledgements	214
9.6	References	214
10	High-throughput Crystallography	217
	<i>Harren Jhoti</i>	
10.1	Introduction	217
10.2	Technological Advances	218
10.2.1	Clone to Crystal	218
10.2.1.1	Protein Production	218
10.2.1.2	Crystallization	219
10.2.2	Crystal to Structure	220
10.2.3	Progress in Structural Genomics	221

10.3	High-throughput Crystallography in Lead Discovery	223
10.3.1	Protein-Ligand Crystal Structures	224
10.4	Fragment-Based Lead Discovery	225
10.4.1	Fragment-Based Lead Discovery Using X-ray Crystallography	226
10.4.2	Structure-Based Optimization of Fragment Hits	229
10.5	Conclusions	230
10.6	Acknowledgements	231
10.7	References	231
11	Micro-Crystallization	235
	<i>Carl L. Hansen, Morten Sommer, Kyle Self, James M. Berger, and Stephen R. Quake</i>	
11.1	Introduction	235
11.2	Microfluidics – Method and Design	237
11.3	Utility of Microfluidics for Crystallization	242
11.4	References	253
	Subject Index	257